DOCSLIB.ORG

Oncology Drug Reference Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oncology Drug Reference Guide Oncology Drug Reference Guide To assure safe and quality care, specialty drugs require a prior authorization and must be obtained from the KSP Specialty pharmacy, 1-833-KSP-4-YOU (1.833.577.4968) BREAST LUNG Send To KSP Send To KSP Send To KSP Send to KSP Afinitor® (everolimus) Lynparza® (olaparib) Alunbrig® (brigatinib) Tagrisso® (osimertinib) Arimidex® (anastrozole) Nerlynx® (neratinib) Gilotrif® (afatinib) Tarceva® (erlotinib) Aromasin® (exemestane) Piqray® (alpelisib) Gilotrif® (afatinib) Tepmetko®(tepotinib) Faslodex® (fulvestrant) Talzenna® (talazoparib) Hycamtin® (topotecan) Vizimpro® (dacomitinib) Femara® (letrozole) Tukysa®(tucatinib) Iressa® (gefitinib) Xalkori® (crizotinib) Ibrance® (palbociclib) Tykerb® (lapatinib) Lorbrena® (lorlatinib) Zykadia® (ceritinib) Kisqali® (ribociclib) Verzenio® (abemaciclib) Mekinist® (trametinib) Send to External pharmacy Xeloda® (capecitabine) Retevmo™ (selpercatinib) Alecensa® (alectinib) HEMATOLOGIC Tabrecta®(capmatinib) Rozlytrek® (entrectinib) Send to KSP Send to KSP MELANOMA Aranesp® (darbopoetin alfa) Promacta® (eltrombopag) Send to KSP Send to KSP Bosulif® (bosutinib) Rydapt® (midostaurin) Braftovi® (encorafenib) Zelboraf® (vemurafenib) Brukinsa® (zanubrutinib) Sprycel® (dasatinib) Mekinist® (trametinib) Send to External pharmacy Calquence® (acalabrutinib) Tasigna® (nilotinib) Mektovi® (binimetinib) Cotellic® (cobimetinib) Doptelet® (avatrombopag) Tavalisse® (fostamatinib) Tafinlar® (dabrafenib) Endari® (glutamine) Tazverik® (tazemetostat) GASTRO/GYN AND OTHER CANCERS Gleevec® (imatinib) Tibsovo® (ivosidenib) Afinitor® (everolimus) Rubraca® (rucaparib) Hydrea®(hydroxyurea) Ukoniq®(umbralisib) Arimidex® (anastrozole) Stivarga® (regorafenib) Iclusig® (ponatinib) Venclexta® (venotoclax) Balversa® (erdafitinib) Sutent® (sunitinib) Idhifa® (enasidenib) Xospata® (gilterinib) Braftovi® (encorafenib) Tarceva® (erlotinib) Imbruvica® (ibrutinib) Xpovio® (selinexor) Cabometyx® (cabozantinib) Tazverik®(tazemetostat) Jakafi® (ruxolitinib) Zolinza® (vorinostat) Gleevec® (imatinib) Votrient® (pazopanib) Ninlaro® (ixazomib) Zydelig® (idelalisib) Hycamtin® (topotecan) Xeloda® (capecitabine) Nplate®(romiplostim) Send to External pharmacy Lenvima® (lenvatinib) Xermelo® (tekitrustat) Oxbtryta® (voxeletor) Pomalyst® (pomalidomide) Lonsurf® (trifluridine) Zejula® (niraparib) Revlimid® (lenalidomide) Lynparza® (olaparib) Send to External pharmacy PROSTATE Nexavar® (sorafenib) Qinlock®(ripretinib) Send to KSP Send to KSP SUPPORTIVE MEDICATIONS Casodex® (bicalutamide) Nubeqa® (darolutamide) Aranesp® (darbopoetin alfa) Nplate® (romiplostim) Erleada® (apalutamide) Rubraca® (rucaparib) Arixtra® (fondaparinux) Prevymis® (letermovir) Eulexin® (flutamide) Xtandi® (enzalutamide) Doptelet® (avatrombopag) Procrit® (epoetin alfa) Lynparza® (olaparib) Zytiga® (abiraterone acetate) Emend® (aprepitant) Promacta® (eltrombopag) RENAL CELL Exjade®(deferasirox) Sancuso® (granisetron) Send to KSP Lenvima® (lenvatinib) Jadenu® (deferasirox) Tavalisse®(fostamatinib) Afinitor® (everolimus) Nexavar® (sorafenib) Lovenox® (enoxaparin) Udenyca (pegfilgrastim) Cabometyx® (cabozantinib) Sutent® (sunitinib) Neulasta® (pegfilgrastim) Xgeva® (denosumab) Fotivda® (tivozanib) Tarceva® (erlotinib) Neupogen® (filgrastim) Zarxio® (filgrastim) Inlyta® (axitinib) Votrient® (pazopanib) NeupogenOnpro®(filgrastim) Zoladex (goserelin) Product with asterisk * = New indication Bolded items are new additions to access list 711 Stephenson Highway, Troy, Michigan 48083 | 1-833-KSP-4-YOU (1-833-577-4968) | [email protected] (rev 7/07/21) Non-Oncology Drug Reference Guide To assure safe and quality care, specialty drugs require a prior authorization and must be obtained from the KSP Specialty pharmacy, 1-833-KSP-4-YOU (1.833.577.4968) ARTHRITIS (PSORIATIC & RHEUMATOID) HEMOPHILIA FACTORS Send To KSP Send To KSP Send to KSP Send To KSP Actemra® Orencia® Advate® Koate-DVI® Cimzia® Otezla® Adynovate® Kogenate FS® Cosentyx® Simponi® Afstyla® Kovaltry® Enbrel® Stelara® Alphanate® NovoEight Humira® Taltz® Alphanine SD® Novoseven® Kevzara® Xeljanz Benefix® Nuwiq® Olumiant® Xeljanz XR® Corifact® Profilnine® CROHN'S DISEASE AND ULCERATIVE COLITIS Eloctate® Recombinate® Send to KSP Send To KSP Feiba® Riastap® Cimzia® Stelara® Helixate ® Rixubis® Humira® Xeljanz® Hemilibra® Vovendi® GROWTH HORMONE/HORMONAL THERAPIES Hemofil® Wilate® Send To KSP Send To KSP Humate-P® Xyntha® Lupron Depot® Nutropin® Idelvion® Norditropin® Zoladex® Jivi® INFERTILITY HEPATITIS C Send To KSP Send to KSP Send To KSP Send To KSP Ganirelix Acetate® Ovidrel® Epclusa® Ribavirin® DERMATOLOGY Harvoni® Sovaldi® Send to KSP Send to KSP Intron A® Vosevi® Cimzia® Otezla® Mavyret® Zepartier® Cosentyx® Remicade® Pegasys® Enbrel® Renflexis® OSTEOPOROSIS Humira® Stelara® Send to KSP Send to KSP Ilumya® Taltz® Forteo® Reclast® Inflectra® Tremfya® Prolia® HYPERLIPIDEMIA TRANSPLANT Send To KSP Send to KSP Send to KSP Send to KSP Praluent® Repatha® Cellcept® Neoral® MISCELLANEOUS Cyclosporine® Prograf® Send to KSP Send to KSP Envarsus XR® Rapamune® Firazyr® Xolair® Gengraf® Sandimmune® Prolia® Mycophenolate Mofetil® Tacrolimus® Myfortic® Zortress® 711 Stephenson Highway, Troy, Michigan 48083 | 1-833-KSP-4-YOU (1-833-577-4968) | [email protected] (rev 7/07/21) Non-Oncology Drug Reference Guide To assure safe and quality care, specialty drugs require a prior authorization and must be obtained from the KSP Specialty pharmacy, 1-833-KSP-4-YOU (1.833.577.4968) HIV MULTIPLE SCLEROSIS Send To KSP Send To KSP Send to KSP Send to KSP Aptivus® Odefsey® Ampyra® Gilenya® Atripla® Pifeltro® Avonex® Glatopa® Biktarvy® Prezcobix® Betaseron® Rebif® Cimduo® Prezista® Copaxone® Tecfidera® Combivir® Retrovir® Extavia® Tysabri® Complera® Reyataz® Delstrigo® Selzentry® Descovy® Stribild® Dovato® Sustiva® Edurant® Symfi® Emtriva® Symfi Lo® Epivir® Symtuza® Epzicom® Temixys® Evotaz® Tivicay® Fuzeon® Triumeq® Intelence® Trizivir® Invirace® Truvada® Isentress® Tybost® Isentress HD® Viracept® Juluca® Viramune® Kaletra® Viread® Lexiva® Ziagen® Norvir® 711 Stephenson Highway, Troy, Michigan 48083 | 1-833-KSP-4-YOU (1-833-577-4968) | [email protected] (rev 7/07/21) Eli Lilly Drug Reference Guide To assure safe and quality care, specialty drugs require a prior authorization and must be obtained from the KSP Specialty pharmacy, 1-833-KSP-4-YOU (1.833.577.4968) BONE MUSCLE JOINT DIABETES Send To KSP Send To KSP Send to KSP Forteo® (teriparatide) Baqsimi® Humulin 70/30® CANCER Basaglar® Humulin N® Send to KSP Glucagon® Humulin R® Retevmo® Verzenio®(abemaciclib) Glyxambi® Humulin R U-500® IMMUNOLOGY Humalog Junior KwikPen® Jardiance® Send to KSP Humalog mix 50/50® Jentadueto® Olumiant® Humalog mix 75/25® JentaduetoXR® NEUROSCIENCE Humalog® Lyumje® Send to KSP Humalog KwikPen® Synjardy® Zyprexa® Relprevv® Tradjenta® TrijardyXR® CARDIOVASCULAR Trulicty® Send to KSP PAIN Adcirca®(tadalafil) Send to KSP Send to KSP Emgality® Reyvow® 711 Stephenson Highway, Troy, Michigan 48083 | 1-833-KSP-4-YOU (1-833-577-4968) | [email protected] (rev 2/24/21) Novo Nordisk Drug Reference Guide To assure safe and quality care, specialty drugs require a prior authorization and must be obtained from the KSP Specialty pharmacy, 1-833-KSP-4-YOU (1.833.577.4968) HAEMOPHILIA DIABETES Send To KSP Send To KSP Send To KSP Send to KSP Esperoct NovoThirteen Actrapid NovoNorm NovoSeven Refixia Fiasp NovoRapid NovoEight Insulatard NovoRapid PumpCart GROWTH DISORDERS Levemir Ozempic Send to KSP Send to KSP Mixtard 30 Rybelsus Macrilen Norditropin Mixtard 40 Ryzodeg 70/30 HORMONE REPLACEMENT THERAPY Mixtard 50 Tresiba Send to KSP Send to KSP NovoMix 30 Victoza Activelle Novofem NovoMix 50 Xultophy Estrofem Trisequens NovoMix 70 Kliogest Vagifem OBESITY Send to KSP Send to KSP Saxenda Wegovy 711 Stephenson Highway, Troy, Michigan 48083 | 1-833-KSP-4-YOU (1-833-577-4968) | [email protected] (rev 7/7/21).
Load more

Recommended publications
  • Antineoplastic Agents
    bmchp.org | 888-566-0008 wellsense.org | 877-957-1300 Pharmacy Policy Antineoplastic Agents Policy Number: 9.700 Version Number: 2.0 Version Effective Date: 9/1/2021 Product Applicability All Plan+ Products Well Sense Health Plan Boston Medical Center HealthNet Plan New Hampshire Medicaid MassHealth- MCO MassHealth- ACO Qualified Health Plans/ConnectorCare/Employer Choice Direct Senior Care Options Note: Disclaimer and audit information is located at the end of this document. Prior Authorization Policy Products Affected: Daurismo™ (glasdegib tablet) Rubraca™ (rucaparib tablets) Erleada™ (apalutamide tablet) Sarclisa® (Isatuximab–IRFC injection) Farydak® (panobinostat capsule) Tazverik™ (tazemetostat tablet) Folotyn® (pralatrexate injection) Talzenna® (talazoparib capsule) Gleostine™ (lomustine capsule) Tibsovo® (ivosidenib tablet) Idhifa® (enasidenib mesylate tablet) Ukoniq (umbralisib tosylate tablet) Lonsurf® (tipiracil hcl and trifluridine tablet) Valchlor™ (mechlorethamine gel) Lynparza™ (olaparib capsule, and tablets) Zejula™ (niraparib capsules) Ninlaro® (ixazomib capsule) Zelboraf® (vemurafenib tablet) Odomzo® (sonidegib capsules) Zytiga® (abiraterone acetate tablet) Pomalyst® (pomalidomide capsule) + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan. Antineoplastic Agents 1 of 4 The Plan may authorize coverage of the above products for members meeting the following criteria: Covered FDA approved indication Use Use supported by: o American Hospital Formulary Service Drug Information o DRUGDEX Information System o United States Pharmacopeia- Drug Information o National Comprehensive Cancer Network (categories 1,2a, and 2b) Medically accepted indications will also be considered for approval.
    [Show full text]
  • PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
    International Journal of Molecular Sciences Review PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects Rosalin Mishra , Hima Patel, Samar Alanazi , Mary Kate Kilroy and Joan T. Garrett * Department of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267-0514, USA; [email protected] (R.M.); [email protected] (H.P.); [email protected] (S.A.); [email protected] (M.K.K.) * Correspondence: [email protected]; Tel.: +1-513-558-0741; Fax: +1-513-558-4372 Abstract: The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted. Keywords: cancer; PIK3CA; resistance; PI3K inhibitors Citation: Mishra, R.; Patel, H.; Alanazi, S.; Kilroy, M.K.; Garrett, J.T.
    [Show full text]
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer
    diagnostics Review Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer Shunsuke Kato Department of Clinical Oncology, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan; [email protected]; Tel.: +81-3-5802-1543 Abstract: The prognosis of patients with solid tumours has remarkably improved with the develop- ment of molecular-targeted drugs and immune checkpoint inhibitors. However, the improvements in the prognosis of pancreatic cancer and biliary tract cancer is delayed compared to other carcinomas, and the 5-year survival rates of distal-stage disease are approximately 10 and 20%, respectively. How- ever, a comprehensive analysis of tumour cells using The Cancer Genome Atlas (TCGA) project has led to the identification of various driver mutations. Evidently, few mutations exist across organs, and basket trials targeting driver mutations regardless of the primary organ are being actively conducted. Such basket trials not only focus on the gate keeper-type oncogene mutations, such as HER2 and BRAF, but also focus on the caretaker-type tumour suppressor genes, such as BRCA1/2, mismatch repair-related genes, which cause hereditary cancer syndrome. As oncogene panel testing is a vital approach in routine practice, clinicians should devise a strategy for improved understanding of the cancer genome. Here, the gene mutation profiles of pancreatic cancer and biliary tract cancer have been outlined and the current status of tumour-agnostic therapy in these cancers has been reported. Keywords: pancreatic cancer; biliary tract cancer; targeted therapy; solid tumours; driver mutations; agonist therapy Citation: Kato, S. Tumour-Agnostic Therapy for Pancreatic Cancer and 1.
    [Show full text]
  • Therapeutic Class Overview Colony Stimulating Factors
    Therapeutic Class Overview Colony Stimulating Factors Therapeutic Class Overview/Summary: This review will focus on the granulocyte colony stimulating factors (G-CSFs) and granulocyte- macrophage colony stimulating factors (GM-CSFs).1-5 Colony-stimulating factors (CSFs) fall under the naturally occurring glycoprotein cytokines, one of the main groups of immunomodulators.6 In general, these proteins are vital to the proliferation and differentiation of hematopoietic progenitor cells.6-8 The G- CSFs commercially available in the United States include pegfilgrastim (Neulasta®), filgrastim (Neupogen®), filgrastim-sndz (Zarxio®), and tbo-filgrastim (Granix®). While filgrastim-sndz and tbo- filgrastim are the same recombinant human G-CSF as filgrastim, only filgrastim-sndz is considered a biosimilar drug as it was approved through the biosimilar pathway. At the time tbo-filgrastim was approved, a regulatory pathway for biosimilar drugs had not yet been established in the United States and tbo-filgrastim was filed under its own Biologic License Application.9 Only one GM-CSF is currently available, sargramostim (Leukine). These agents are Food and Drug Administration (FDA)-approved for a variety of conditions relating to neutropenia or for the collection of hematopoietic progenitor cells for collection by leukapheresis.1-5 Due to the pathway taken, tbo-filgrastim does not share all of the same indications as filgrastim and these two products are not interchangeable. It is important to note that although filgrastim-sndz is a biosimilar product, and it was approved with all the same indications as filgrastim at the time, filgrastim has since received FDA-approval for an additional indication that filgrastim-sndz does not have, to increase survival in patients with acute exposure to myelosuppressive doses of radiation.1-3A complete list of indications for each agent can be found in Table 1.
    [Show full text]
  • PRIOR AUTHORIZATION CRITERIA for APPROVAL Initial Evaluation Target Agent(S) Will Be Approved When ONE of the Following Is Met: 1
    Self-Administered Oncology Agents Through Preferred Prior Authorization Program Summary FDA APPROVED INDICATIONS3-104 Please reference individual agent product labeling. CLINICAL RATIONALE For the purposes of the Self -Administered Oncology Agents criteria, indications deemed appropriate are those approved in FDA labeling and/or supported by NCCN Drugs & Biologics compendia with a category 1 or 2A recommendation, AHFS, or DrugDex with level of evidence of 1 or 2A. SAFETY3-104 Agent(s) Contraindication(s) Afinitor/Afinitor Disperz Hypersensitivity to everolimus, to other rapamycin (everolimus) derivatives None Alecensa (alectinib) Alunbrig (brigatinib) None Ayvakit (avapritinib) None Balversa (erdafitinib) None Hypersensitivity to bosutinib Bosulif (bosutinib) Braftovi (encorafenib) None Brukinsa (zanubrutinib) None Cabometyx None (cabozantinib) Calquence None (acalabrutinib) Caprelsa Congenital long QT syndrome (vandetanib) Cometriq None (cabozantinib) Copiktra (duvelisib) None Cotellic (cobimetinib) None Daurismo (glasdegib) None None Erivedge (vismodegib) Erleada (apalutamide) Pregnancy None Farydak (panobinostat) Fotivda (tivozanib) None Gavreto (pralsetinib) None None Gilotrif (afatinib) Gleevec None (imatinib) Hycamtin Severe hypersensitivity to topotecan (topotecan) None Ibrance (palbociclib) KS_PS_SA_Oncology_PA_ProgSum_AR1020_r0821v2 Page 1 of 19 © Copyright Prime Therapeutics LLC. 08/2021 All Rights Reserved Effective: 10/01/2021 Agent(s) Contraindication(s) None Iclusig (ponatinib) Idhifa (enasidenib) None Imbruvica (ibrutinib)
    [Show full text]
  • Pharmacy Pre-Authorization Criteria
    PHARMACY PRE-AUTHORIZATION CRITERIA DRUG (S) Oncology Medications: Sprycel (dasatinib) Afinitor (everolimus) Stivarga (regorafenib) Caprelsa (vandetanib) Sutent (sunitinib) Gilotrif (afatinib dimaleate) Tarceva (erlotinob) Gleevec (imatinib mesylate) Temodar (temozolomide) Ibrance (palbociclib) Tepadina (thiotepa) Idhifa (enasidenib) Thalomid (thalidomide) Iressa (gefitinib) Vantas (histrelin acetate) Kisqali (ribociclib) Venclexta (venetoclax) Lenvima (lenvatinib) Verzenio (abemaciclib) Nerlynx (neratinib) Vidaza (azacitidine) Nexavar (sorafenib) Votrient (pazopanib) Ninlaro (ixazomib) Xalkori (crizotinib) Odomzo (sonidegib) Xeloda (capecitabine) Zydelig (idelalisib) Zykadia (certinib) Zytiga (abiraterone acetate) PHARMACY PRE-AUTHORIZATION CRITERIA POLICY # 21107 CRITERIA The above medications are covered when the following criteria are met: 1. Ordered by an oncologist or hematologist AND 2. All FDA Approved Indications OR 3. Chemo agent is listed in an accepted Compendia for treatment of cancer type, OR - National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, level of evidence 1, 2A, or 2B - Thomson Micromedex DrugDex - Chemo agent is recommended for cancer type in formal clinical studies published in at least 2 peer reviewed professional medical journals, published in the United States or Great Britain Coverage Duration: Initial: 3 months Continuation: 6 months. Afinitor, Gilotrif, Gleevec, Ibrance, Idhifa, Iressa, Kisqali, Lenvima, Nexavar, Ninlaro, Odomzo, Sprycel, Stivarga, Sutent, Tarceva, Temodar, Thalomid,
    [Show full text]
  • FULPHILA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULPHILA safely and effectively. See full prescribing information for -----------------------WARNINGS AND PRECAUTIONS----------------------­ FULPHILA. • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. (5.1) ™ FULPHILA (pegfilgrastim-jmdb) injection, for subcutaneous use • Acute respiratory distress syndrome (ARDS): Evaluate patients who Initial U.S. Approval: 2018 develop fever, lung infiltrates, or respiratory distress. Discontinue ™ ® Fulphila in patients with ARDS. (5.2) FULPHILA (pegfilgrastim-jmdb) is biosimilar* to NEULASTA • Serious allergic reactions, including anaphylaxis: Permanently (pegfilgrastim). (1) discontinue Fulphila in patients with serious allergic reactions. (5.3) • Fatal sickle cell crises: Have occurred. (5.4) ----------------------------INDICATIONS AND USAGE--------------------------- • Glomerulonephritis: Evaluate and consider dose-reduction or Fulphila is a leukocyte growth factor indicated to interruption of Fulphila if causality is likely. (5.5) • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving ------------------------------ADVERSE REACTIONS------------------------------ myelosuppressive anti-cancer drugs associated with a clinically Most common adverse reactions (≥ 5% difference in incidence compared to significant incidence of febrile neutropenia.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • 211192Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211192Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Division of Risk Management (DRISK) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type NDA Application Number 211192 PDUFA Goal Date August 21, 2018 OSE RCM # 2017-2612; 2017-2614 Reviewer Name(s) Till Olickal, Ph.D., Pharm.D. Team Leader Elizabeth Everhart, MSN, RN, ACNP Division Director Cynthia LaCivita, Pharm.D. Review Completion Date June 6, 2018 Subject Review to determine if a REMS is necessary Established Name Ivosidenib Trade Name Tibsovo Name of Applicant Agios Pharmaceuticals, Inc. Therapeutic Class Isocitrate dehydrogenase-1 inhibitor Formulation(s) 250 mg tablet Dosing Regimen 500 mg orally once daily until disease progression or unacceptable toxicity. 1 Reference ID: 4273770 Table of Contents EXECUTIVE SUMMARY ......................................................................................................................................................... 3 1 Introduction ..................................................................................................................................................................... 3 2 Background ...................................................................................................................................................................... 3 2.1 Product Information ..........................................................................................................................................
    [Show full text]
  • Treatment of MDS in 2014 and Beyond Treatment Goals in MDS
    5/22/2014 Treatment of MDS in 2014 and Beyond Treatment goals in MDS • Get rid of it May 17, 2014 • If you can’t do that, make life better and longer – Improve blood counts Gail J. Roboz, M.D. – Improve quality of life Director, Leukemia Program – Decrease time to progression/leukemia Associate Professor of Medicine Hematopoietic Growth Factors: Hematopoietic Growth Factors: What are they? What are they? • Erythropoietin (EPO,Procrit®, Epogen®) – red • Synthetic versions of proteins normally • Granulocyte colony stimulating factor (GCSF, made in the body to stimulate growth of red Neupogen®) – white cells, white cells and platelets • Granulocyte-macrophage colony stimulating • Promote growth and differentiation factor (GM-CSF, Leukine®) – white • Thrombopoietin (TPO, romiplostim, Nplate®) – • Inhibitors of apoptosis (cell death) platelets • Darbepoietin (Aranesp®) • Peg-filgrastim (Neulasta®) • Note, these are not FDA-approved for MDS Erythropoietin (epo) in MDS Erythropoietin (epo) in MDS • Anemia is presents in >80% of MDS pts at dx • Often high endogenous epo levels • Transfusions help, but many issues • Many different doses and schedules • Recombinant EPO is FDA-approved for treating • Higher response rates with epo + G-CSF if anemia associated with kidney failure epo ≤500 mU/mL and transfusions <2 • Has been used since about 1990 in MDS U/month • Response rates in about 15-30% of patients • Poor probability of response if epo >500 • Many different studies including >1000 patients mU/mL and transfusions >2 U/month • Part of the NCCN MDS treatment guidelines 1. Casadevall N, et al. Blood. 2004;104:321-327. 2. Hellstrom-Lindberg E. Br J Haematol. 1995;89:67-71.
    [Show full text]
  • Horizon Scanning Status Report June 2019
    Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. A representative from PCORI served as a contracting officer’s technical representative and provided input during the implementation of the horizon scanning system. PCORI does not directly participate in horizon scanning or assessing leads or topics and did not provide opinions regarding potential impact of interventions. Financial Disclosure Statement None of the individuals compiling this information have any affiliations or financial involvement that conflicts with the material presented in this report. Public Domain Notice This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. All statements, findings, and conclusions in this publication are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors.
    [Show full text]